Special 301: U.S. Gov't "Watch List" Threatens Access to Meds

Special 301 is an annual report by the Office of the US Trade Representative (USTR) which places countries on a “watch list” if USTR would like to see greater changes in their intellectual property rules or enforcement practice.The USTR articulates in past Special 301 Reports that “the United States respects a trading partner’s right to protect public health and, in particular, to promote access to medicines for all,” and “the United States respects its trading partners’ rights to grant compulsory licenses in a manner consistent with the provisions of the TRIPS Agreement.” However, in these same reports, USTR has frequently criticized countries for exercising public health rights and other flexibilities enshrined in the TRIPS Agreement and Doha Declaration. Every year the USTR hears public comments on the Special 301 review.

See the USTR 2017 Special 301 Report Here.

Our Past Submissions on the Special 301 Report:

Select News Coverage on Special 301 Report:

Blog Posts on special 301:

Return to Access to Medicines Page